AbbVie Inc. (ABBV) To Go Ex-Dividend on October 15th

AbbVie Inc. (NYSE:ABBV) declared a quarterly dividend on Thursday, September 10th. Shareholders of record on Thursday, October 15th will be paid a dividend of 1.73 per share on Monday, November 16th. This represents a c) annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Thursday, October 15th.

AbbVie has raised its dividend payment by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 53 consecutive years. AbbVie has a dividend payout ratio of 49.5% indicating that its dividend is sufficiently covered by earnings. Research analysts expect AbbVie to earn $16.15 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 42.8%.

AbbVie Stock Up 0.8%

Shares of AbbVie stock opened at $257.17 on Friday. AbbVie has a 52 week low of $190.75 and a 52 week high of $267.47. The business has a 50 day moving average price of $254.46 and a 200-day moving average price of $230.94. The company has a market cap of $454.36 billion, a PE ratio of 72.65, a price-to-earnings-growth ratio of 1.15 and a beta of 0.29.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the firm posted $2.97 EPS. AbbVie’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, research analysts anticipate that AbbVie will post 14.05 EPS for the current year.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.